A trial assessing relation between serum Interferon-inducible protein 10 (IP10) levels and HBsAg serum levels in patients with compensated HBeAg-neg-ative chronic hepatitis B (CHBe-) patients treated with tenofovir disoproxil fumarate (TDF)

Trial Profile

A trial assessing relation between serum Interferon-inducible protein 10 (IP10) levels and HBsAg serum levels in patients with compensated HBeAg-neg-ative chronic hepatitis B (CHBe-) patients treated with tenofovir disoproxil fumarate (TDF)

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2015

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B
  • Focus Pharmacokinetics
  • Most Recent Events

    • 15 Dec 2015 New trial record
    • 05 Nov 2013 Interim results (n=137) presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top